Epidemic Intelligence Service, Office of Workforce and Career Development, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
N Engl J Med. 2011 Sep 22;365(12):1108-17. doi: 10.1056/NEJMoa1000446.
Routine vaccination of U.S. infants with pentavalent rotavirus vaccine (RV5) began in 2006.
Using MarketScan databases, we assessed RV5 coverage and diarrhea-associated health care use from July 2007 through June 2009 versus July 2001 through June 2006 in children under 5 years of age. We compared the rates of diarrhea-associated health care use in unvaccinated children in the period from January through June (when rotavirus is most prevalent) in 2008 and 2009 with the prevaccine rates to estimate indirect benefits. We estimated national reductions in the number of hospitalizations for diarrhea, and associated costs, by extrapolation.
By December 31, 2008, at least one dose of RV5 had been administered in 73% of children under 1 year of age, 64% of children 1 year of age, and 8% of children 2 to 4 years of age. Among children under 5 years of age, rates of hospitalization for diarrhea in 2001-2006, 2007-2008, and 2008-2009 were 52, 35, and 39 cases per 10,000 person-years, respectively, for relative reductions from 2001-2006 by 33% (95% confidence interval [CI], 31 to 35) in 2007-2008 and by 25% (95% CI, 23 to 27) in 2008-2009; rates of hospitalization specifically coded for rotavirus infection were 14, 4, and 6 cases per 10,000 person-years, respectively, for relative reductions in the rate from 2001-2006 by 75% (95% CI, 72 to 77) in 2007-2008 and by 60% (95% CI, 58 to 63) in 2008-2009. In the January-June periods of 2008 and 2009, the respective relative rate reductions among vaccinated children as compared with unvaccinated children were as follows: hospitalization for diarrhea, 44% (95% CI, 33 to 53) and 58% (95% CI, 52 to 64); rotavirus-coded hospitalization, 89% (95% CI, 79 to 94) and 89% (95% CI, 84 to 93); emergency department visits for diarrhea, 37% (95% CI, 31 to 43) and 48% (95% CI, 44 to 51); and outpatient visits for diarrhea, 9% (95% CI, 6 to 11) and 12% (95% CI, 10 to 15). Indirect benefits (in unvaccinated children) were seen in 2007-2008 but not in 2008-2009. Nationally, for the 2007-2009 period, there was an estimated reduction of 64,855 hospitalizations, saving approximately $278 million in treatment costs.
Since the introduction of rotavirus vaccine, diarrhea-associated health care utilization and medical expenditures for U.S. children have decreased substantially.
美国婴儿于 2006 年开始常规接种五价轮状病毒疫苗(RV5)。
使用 MarketScan 数据库,我们评估了 2007 年 7 月至 2009 年 6 月期间 5 岁以下儿童中 RV5 疫苗的覆盖率和与腹泻相关的医疗保健使用情况,与 2001 年 7 月至 2006 年 6 月相比。我们比较了 2008 年和 2009 年 1 月至 6 月(轮状病毒最流行的时期)期间未接种疫苗的儿童腹泻相关医疗保健使用的比率,以估计间接效益。我们通过外推法估计了因腹泻住院的人数和相关费用的全国减少量。
截至 2008 年 12 月 31 日,至少有一剂 RV5 疫苗已接种于 73%的 1 岁以下儿童、64%的 1 岁儿童和 8%的 2 至 4 岁儿童。在 5 岁以下的儿童中,2001-2006 年、2007-2008 年和 2008-2009 年因腹泻住院的比率分别为每 10000 人年 52、35 和 39 例,与 2001-2006 年相比,2007-2008 年的相对减少率为 33%(95%置信区间[CI],31 至 35),2008-2009 年的相对减少率为 25%(95%CI,23 至 27);专门编码为轮状病毒感染的住院病例分别为每 10000 人年 14、4 和 6 例,与 2001-2006 年相比,2007-2008 年的相对减少率为 75%(95%CI,72 至 77),2008-2009 年的相对减少率为 60%(95%CI,58 至 63)。在 2008 年和 2009 年的 1 月至 6 月期间,与未接种疫苗的儿童相比,接种疫苗的儿童的相对减少率分别为:腹泻住院,44%(95%CI,33 至 53)和 58%(95%CI,52 至 64);轮状病毒编码的住院治疗,89%(95%CI,79 至 94)和 89%(95%CI,84 至 93);腹泻急诊就诊,37%(95%CI,31 至 43)和 48%(95%CI,44 至 51);以及腹泻门诊就诊,9%(95%CI,6 至 11)和 12%(95%CI,10 至 15)。2007-2008 年观察到间接效益(在未接种疫苗的儿童中),但 2008-2009 年未观察到。在 2007-2009 年期间,全国估计减少了 64855 例住院治疗,节省了约 2.78 亿美元的治疗费用。
自轮状病毒疫苗问世以来,美国儿童与腹泻相关的医疗保健利用和医疗支出已大幅减少。